PDS BIOTECHNOLOGY CORPORATION - COMMON STOCK

PDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI Conference

06 9 2023 08:00:00 提供 Nasdaq GlobeNewswire

PDS Biotech Announces Data from IMMUNOCERV Phase 2 Trial Investigating PDS0101 and Chemoradiotherapy in Cervical Cancer to be Featured in Oral Presentation at the ASTRO 2023 Annual Meeting

16 8 2023 08:00:01 提供 Nasdaq GlobeNewswire

PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update

14 8 2023 07:30:00 提供 Nasdaq GlobeNewswire

PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial

14 8 2023 07:00:01 提供 Nasdaq GlobeNewswire

PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2023 Financial Results

07 8 2023 08:00:01 提供 Nasdaq GlobeNewswire

PDS Biotech to Present at BTIG Virtual Biotechnology Conference 2023

02 8 2023 08:00:02 提供 Nasdaq GlobeNewswire

PDS Biotech Announces Acceptance of Abstract on Combination of PDS0301 with Docetaxel in Metastatic Prostate Cancer for Oral Presentation by the National Cancer Institute at Cytokines 2023

17 7 2023 08:00:01 提供 Nasdaq GlobeNewswire

PDS Biotech Strengthens Intellectual Property Portfolio Governing A Combination of Versamune® and PDS0301

11 7 2023 08:00:01 提供 Nasdaq GlobeNewswire

PDS Biotechnology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 6 2023 16:05:00 提供 Nasdaq GlobeNewswire

PDS Biotech to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023

20 6 2023 08:00:01 提供 Nasdaq GlobeNewswire

PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 and KEYTRUDA® in Head and Neck Cancer

14 6 2023 08:00:01 提供 Nasdaq GlobeNewswire

PDS Biotechnology Post-ASCO Conference Call Tomorrow, June 6, at 8 a.m. ET

05 6 2023 14:52:38 提供 Nasdaq GlobeNewswire

PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients

25 5 2023 17:00:00 提供 Nasdaq GlobeNewswire

PDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer

18 5 2023 08:00:01 提供 Nasdaq GlobeNewswire

PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial Results

15 5 2023 07:30:00 提供 Nasdaq GlobeNewswire

PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2023 Financial Results

04 5 2023 08:00:01 提供 Nasdaq GlobeNewswire

PDS Biotech to Present Updated Data at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Highlighting Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients

27 4 2023 08:00:01 提供 Nasdaq GlobeNewswire

PDS Biotech Receives $1.4 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program

24 4 2023 08:00:01 提供 Nasdaq GlobeNewswire

PDS Biotech Supports Oral, Head & Neck Cancer Awareness Month During April and Oral, Head & Neck Cancer Awareness Week from April 16-22, 2023

03 4 2023 08:00:01 提供 Nasdaq GlobeNewswire

PDS Biotech Announces Plan to Initiate Phase 3 Study Evaluating PDS0101 in Combination with KEYTRUDA® in Head and Neck Cancer in 2023

30 3 2023 08:00:00 提供 Nasdaq GlobeNewswire